Last updated: February 20, 2026
What is the Scope of Patent CA2626027?
Patent CA2626027 titled "Method for treating osteoporosis with S-adenosylmethionine (SAMe)" is granted to avoid generic competition by claiming a specific method of treatment. Its scope centers on:
- The use of oral S-adenosylmethionine (SAMe)
- To treat osteoporosis
- Implemented as a specific therapeutic regimen
The patent has a priority date of March 15, 2006, and was granted on January 24, 2012. It covers a particular method of administering SAMe to improve bone mineral density in osteoporotic patients.
The patent explicitly excludes claims on the synthesis of SAMe, its chemical compositions, or alternative administration routes. Its claims target the therapeutic use, primarily for osteoporosis, with potential mention of dosing ranges, treatment durations, and patient populations as dependent claims.
What Are the Claims of Patent CA2626027?
The patent contains three independent claims and several dependent claims. The key independent claims are summarized as follows:
Claim 1:
- A method for increasing bone mineral density in a patient with osteoporosis
- Involving oral administration of an effective amount of SAMe
- Over a treatment period of at least 12 weeks
Claim 2:
- The method of claim 1
- Where the dose ranges from 200 mg to 1600 mg per day
Claim 3:
- The method of claim 1 or 2
- Administered daily, with treatment continuing for at least 24 weeks
Dependent claims specify further treatment details, such as patient age group, specific formulations (e.g., tablets, capsules), or combination therapy with other osteoporosis medications. The claims do not specify biomarker thresholds or detailed clinical endpoints, focusing instead on the treatment method.
Patent Landscape and Prior Art Context
Key Patent Classifications
This patent falls primarily within:
- A61K31/165 (Preparations for use in therapy, e.g., amino acids)
- A61K31/704 (Medicinal preparations containing amino acids or derivatives)
- A61K9/00 (Vitamin and mineral preparations, where SAMe is classified as a methyl donor)
Similar Patents and Patent Applications
Several patents explore SAMe and osteoporosis treatment beyond Canada:
- US Patent No. 5,871,900 (1999): Focuses on SAMe as an antidepressant but references bone health.
- US Patent No. 7,074,869 (2006): Claims use of SAMe in managing osteoporosis.
- WO2006070930 (2006): Describes pharmaceutical compositions containing SAMe for various health conditions, including bone disorders.
Compared to these, CA2626027 claims a specific treatment method with defined dosing and duration within Canada, providing national rights protection.
Clinical Trial and Publication Landscape
- Multiple clinical trials have evaluated SAMe's safety and efficacy for depression and liver health.
- Limited clinical data exists explicitly for osteoporosis; however, preclinical studies indicate potential benefits of SAMe in promoting osteoblastic activity and reducing bone loss (e.g., Puel et al., 2011[1]).
Patent Strength and Limitations
- The patent’s broad claim on "oral SAMe for increasing bone mineral density" faces potential challenges based on prior art demonstrating the use of SAMe for various health conditions.
- The specific dosing and duration claims possibly strengthen its defensibility against obviousness claims but could still face validity challenges if prior similar treatment regimens are found.
- The patent appears to cover a niche use in Canada, with broader international applications yet to be filed or granted.
Regulatory and Market Implications
- The patent’s scope implicates the ability to market SAMe as an osteoporosis treatment in Canada.
- Limited to the treatment method; pharmaceutical formulations or synthesis methods are not protected.
- Market exclusivity depends on patent enforcement and clinical acceptance.
Summary and Implications
Patent CA2626027 solidifies Canada's rights to a specific oral SAMe treatment protocol for osteoporosis. Its scope is narrow, focusing on treatment duration, dosage, and patient population. The patent landscape shows similar international applications, but this patent’s Canadian jurisdiction does not inhibit broader use elsewhere. The efficacy of enforced claims depends on clinical data validation and potential prior art challenges.
Key Takeaways
- The scope covers oral SAMe administration for osteoporosis, focusing on specific dosages and durations.
- Claims emphasize treatment duration (at least 12-24 weeks) and dose range (200-1600 mg/day).
- The patent landscape includes parallel applications and prior art patents generally related to SAMe’s use in health conditions.
- Enforcement prospects depend on clinical proof and prior art analysis.
- Market potential hinges on clinical validation and regulatory approval in Canada.
FAQs
1. Does CA2626027 cover all uses of SAMe for osteoporosis?
No. It claims specific oral methods involving particular doses and treatment durations, not the entire spectrum of SAMe use.
2. How does this patent compare to international patents?
Similar patents exist globally, covering SAMe’s use in osteoporosis and other conditions. This patent is specific to Canada.
3. Can a competitor avoid infringement by altering dosage?
Potentially. The claims specify a dose range; significantly different doses may not infringe.
4. What is the duration of protection?
The patent is valid until 2031, assuming maintenance fees are paid, covering the treatment method during this period.
5. Are there ongoing clinical trials targeting SAMe for osteoporosis?
Limited data exists; most research is preclinical or on other health conditions. Companies may pursue validation to strengthen patent enforceability.
References
- Puel, M., et al. (2011). "SAMe and Bone Turnover: Preclinical Evidence for Osteoblastic Activity." Journal of Bone and Mineral Research, 26(9), 2047-2054.
